Dose‐Dependent Risk of Neutropenia after 7‐Day Courses of Artesunate Monotherapy in Cambodian Patients with Acute <i>Plasmodium falciparum</i> Malaria

Abstract

Artesunate remains a crucial drug for the treatment of malaria, and determining optimal dosing regimens is vital to overcome emerging resistant parasite strains along the Thai-Cambodian border. However, future experimental dosing studies must be designed with care, because the safety of such regimens can no longer be assumed. The artemisinin derivatives remain one of the safest classes of antimalarial drugs, but this study demonstrates that the dosing limit may have been reached.